Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via avß3 integrin in myeloma cells

Oncotarget

Volumn 5, Issue 15, 2014, Pages 6312-6322

  Cohen, Keren ^a,b   Flint, Nir ^a,b   Shalev, Shahar ^a,b   Erez, Daniel ^a,b   Baharal, Tal ^a,b   Davis, Paul J ^c   Hercbergs, Aleck ^d   Ellis, Martin ^a,b   Ashur Fabian, Osnat ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ALBANY MEDICAL COLLEGE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adhesion; Integrin; MMP 9; Myeloma; Thyroid hormone

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BORTEZOMIB; FIBRONECTIN; GELATINASE B; LIOTHYRONINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NANOPARTICLE; THYROID HORMONE; THYROXINE; VITRONECTIN RECEPTOR; ALPHAVBETA5 INTEGRIN; MMP9 PROTEIN, HUMAN; TETRAIODOTHYROACETIC ACID;

ADULT; AGED; ARTICLE; CELL ADHESION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN EXPRESSION; PROTEIN SECRETION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

BORTEZOMIB; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; MATRIX METALLOPROTEINASE 9; MULTIPLE MYELOMA; RECEPTORS, VITRONECTIN; THYROXINE; TRIIODOTHYRONINE;

EID: 84906257870     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2205     Document Type: Article

References (49)

1. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, et al. International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stemcell transplantation. J Clin Oncol. 2014; 32(6):587-600.
2. Vallet S and Podar K. New insights, recent advances, and current challenges in the biological treatment of multiple myeloma. Expert Opin Biol Ther. 2013; 13 Suppl 1:S35-53.
3. Abdi J, Chen G and Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013; 4(12):2186-2207.
4. Vande Broek I, Vanderkerken K, Van Camp B and Van Riet I. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis. 2008; 25(4):325-334.
5. Van Valckenborgh E, Bakkus M, Munaut C, Noel A, St Pierre Y, Asosingh K, Van Riet I, Van Camp B and Vanderkerken K. Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int J Cancer. 2002; 101(6):512-518.
6. Vande Broek I, Asosingh K, Allegaert V, Leleu X, Facon T, Vanderkerken K, Van Camp B and Van Riet I. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia. 2004; 18(5):976-982.
7. Barille S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, Bataille R and Amiot M. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood. 1997; 90(4):1649-1655.
8. Skliris A, Labropoulou VT, Papachristou DJ, Aletras A, Karamanos NK and Theocharis AD. Cell-surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases. Febs J. 2013; 280(10):2342-2352.
9. Segarra M, Vilardell C, Matsumoto K, Esparza J, Lozano E, Serra-Pages C, Urbano-Marquez A, Yamada KM and Cid MC. Dual function of focal adhesion kinase in regulating integrin-induced MMP-2 and MMP-9 release by human T lymphoid cells. Faseb J. 2005; 19(13):1875-1877.
10. Esparza J, Vilardell C, Calvo J, Juan M, Vives J, Urbano- Marquez A, Yague J and Cid MC. Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. Blood. 1999; 94(8):2754-2766.
11. Frassanito MA, Rao L, Moschetta M, Ria R, Di Marzo L, De Luisi A, Racanelli V, Catacchio I, Berardi S, Basile A, Menu E, Ruggieri S, Nico B, Ribatti D, Fumarulo R, Dammacco F, et al. Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies. Leukemia. 2013.
12. Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F and Dammacco F. Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple MM. Haematologica. 2002; 87(8):836-845.
13. Vacca A, Ria R, Presta M, Ribatti D, Iurlaro M, Merchionne F, Tanghetti E and Dammacco F. Avb3 integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Experimental Hematology. 2001; 29:993-1003.
14. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S and Davis PJ. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology. 2005; 146(7):2864-2871.
15. Cohen K, Ellis M, Khoury S, Davis PJ, Hercbergs A and Ashur-Fabian O. Thyroid hormone is a MAPK-dependent growth factor for human myeloma cells acting via alphavbeta3 integrin. Mol Cancer Res. 2011; 9(10):1385- 1394.
16. Davis PJ, Davis FB, Mousa SA, Luidens MK and Lin HY. Membrane receptor for thyroid hormone: physiologic andpharmacologic implications. Annu Rev Pharmacol Toxicol. 2011; 51:99-115.
17. Hercbergs A, Davis F, Lin H, Luidens M, Meng R, Ashur- Fabian O, Mousa S and Davis P. Integrin-Mediated Actions of Thyroid Hormone Analogues on Tumor Cell Chemosensitivity, Integrin-Growth Factor Receptor Crosstalk and Inflammatory Gene Expression. Cancer and Clinical Oncology. 2012; 1(1):32-40.
18. Oki N, Matsuo H, Nakago S, Murakoshi H, Laoag-Fernandez JB and Maruo T. Effects of 3,5,3'-triiodothyronine on the invasive potential and the expression of integrins and matrix metalloproteinases in cultured early placental extravillous trophoblasts. J Clin Endocrinol Metab. 2004; 89(10):5213-5221.
19. Trentin AG, De Aguiar CB, Garcez RC and Alvarez-Silva M. Thyroid hormone modulates the extracellular matrix organization and expression in cerebellar astrocyte: effects on astrocyte adhesion. Glia. 2003; 42(4):359-369.
20. Ribeiro-Carvalho MM, Farias-de-Oliveira DA, Villa- Verde DM and Savino W. Triiodothyronine modulates extracellular matrix-mediated interactions between thymocytes and thymic microenvironmental cells. Neuroimmunomodulation. 2002; 10(3):142-152.
21. Villa-Verde DM, de Mello-Coelho V, Farias-de-Oliveira DA, Dardenne M and Savino W. Pleiotropic influence of triiodothyronine on thymus physiology. Endocrinology. 1993; 133(2):867-875.
22. Liao CH, Yeh SC, Huang YH, Chen RN, Tsai MM, Chen WJ, Chi HC, Tai PJ, Liao CJ, Wu SM, Cheng WL, Pai LM and Lin KH. Positive regulation of spondin 2 by thyroid hormone is associated with cell migration and invasion. Endocr Relat Cancer. 2010; 17(1):99-111.
23. Dietrich JB, Zaepfel M and Kuchler-Bopp S. Expression of intercellular adhesion molecule-1 in C6 glioma cells is up-regulated by thyroid hormone. Neuroreport. 2000; 11(13):2855-2860.
24. Cheng S, Leonard J and Davis P. Molecular aspects of thyroid hormone actions. Endocr Rev. 2010; 31(2):139-170.
25. Farwell AP, Tranter MP and Leonard JL. Thyroxinedependent regulation of integrin-laminin interactions in astrocytes. Endocrinology. 1995; 136(9):3909-3915.
26. Caers J, Gunthert U, De Raeve H, Van Valckenborgh E, Menu E, Van Riet I, Van Camp B and Vanderkerken K. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br J Haematol. 2006; 132(4):469-477.
27. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F and Dammacco F. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple MM. Blood 1999; 93(9):3064-3073.
28. Vacca A, Ribatti D, Roccaro AM, Ria R, Palermo L and Dammacco F. Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma. Acta Haematol. 2001; 106(4):162-169.
29. Segarra M, Lozano E, Corbera-Bellalta M, Vilardell C, Cibeira MT, Esparza J, Izco N, Blade J and Cid MC. Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. Haematologica. 2010; 95(3):456-463.
30. Chen YF, Weltman NY, Li X, Youmans S, Krause D and Gerdes AM. Improvement of left ventricular remodeling after myocardial infarction with eight weeks L-thyroxine treatment in rats. J Transl Med. 2013; 11:40.
31. Rae MT, Gubbay O, Kostogiannou A, Price D, Critchley HO and Hillier SG. Thyroid hormone signaling in human ovarian surface epithelial cells. J Clin Endocrinol Metab. 2007; 92(1):322-327.
32. Fu L, Sun G, Fiorentino M and Shi YB. Characterization of Xenopus tissue inhibitor of metalloproteinases-2: a role in regulating matrix metalloproteinase activity during development. PLoS One. 2012; 7(5):e36707.
33. Chi HC, Chen SL, Liao CJ, Liao CH, Tsai MM, Lin YH, Huang YH, Yeh CT, Wu SM, Tseng YH, Chen CY, Tsai CY, Chung IH, Chen WJ and Lin KH. Thyroid hormone receptors promote metastasis of human hepatoma cells via regulation of TRAIL. Cell Death Differ. 2012; 19(11):1802- 1814.
34. Chen RN, Huang YH, Lin YC, Yeh CT, Liang Y, Chen SL and Lin KH. Thyroid hormone promotes cell invasion through activation of furin expression in human hepatoma cell lines. Endocrinology. 2008; 149(8):3817-3831.
35. Purushothaman A, Chen L, Yang Y and Sanderson RD. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem. 2008; 283(47):32628-32636.
36. Stefanidakis M and Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood. 2006; 108(5):1441-1450.
37. Skandalis SS, Aletras AJ, Gialeli C, Theocharis AD, Afratis N, Tzanakakis GN and Karamanos NK. Targeting the tumor proteasome as a mechanism to control the synthesis and bioactivity of matrix macromolecules. Curr Mol Med. 2012; 12(8):1068-1082.
38. Karthik S, Sankar R, Varunkumar K and Ravikumar V. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. Biomed Pharmacother. 2014.
39. Ikebe T, Takeuchi H, Jimi E, Beppu M, Shinohara M and Shirasuna K. Involvement of proteasomes in migration and matrix metalloproteinase-9 production of oral squamous cell carcinoma. Int J Cancer. 1998; 77(4):578-585.
40. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar- Eli M, Millikan R, Shen Y, Dinney CP and McConkey DJ. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther. 2004; 3(3):279-290.
41. Jones MD, Liu JC, Barthel TK, Hussain S, Lovria E, Cheng D, Schoonmaker JA, Mulay S, Ayers DC, Bouxsein ML, Stein GS, Mukherjee S and Lian JB. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res. 2010; 16(20):4978-4989.
42. Lee JH, Chiang SY, Nam D, Chung WS, Lee J, Na YS, Sethi G and Ahn KS. Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP- 1 and SHP-2 tyrosine phosphatases. Cancer Lett. 2014; 345(1):140-148.
43. Himelstein BP, Lee EJ, Sato H, Seiki M and Muschel RJ. Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line. Oncogene. 1997; 14(16):1995-1998.
44. Weis SM, Stupack DG and Cheresh DA. Agonizing integrin antagonists? Cancer Cell. 2009; 15(5):359-361.
45. Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HY and Davis PJ. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis. 2008; 11(2):183-190.
46. Sun CY, Hu Y, Guo T, Wang HF, Zhang XP, He WJ and Tan H. Resveratrol as a novel agent for treatment of multiple myeloma with matrix metalloproteinase inhibitory activity. Acta Pharmacol Sin. 2006; 27(11):1447-1452.
47. Davis PJ, Mousa SA, Cody V, Tang HY and Lin HY. Small molecule hormone or hormone-like ligands of integrin alphaVbeta3: implications for cancer cell behavior. Horm Cancer. 2013; 4(6):335-342.
48. Lin HY, Tang HY, Keating T, Wu YH, Shih A, Hammond D, Sun M, Hercbergs A, Davis FB and Davis PJ. Resveratrol is pro-apoptotic and thyroid hormone is antiapoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis. 2008; 29(1):62-69.
49. Lin HY, Lansing L, Merillon JM, Davis FB, Tang HY, Shih A, Vitrac X, Krisa S, Keating T, Cao HJ, Bergh J, Quackenbush S and Davis PJ. Integrin alphaVbeta3 contains a receptor site for resveratrol. Faseb J. 2006; 20(10):1742-1744.